What changed in Halozyme Therapeutics, Inc.'s latest annual report
In the year ended 31 Dec 2025, Halozyme Therapeutics, Inc.'s revenue rose 37.6% to USD 1.40bn, from USD 1.02bn; net income fell 28.6% to USD 316.89m, from USD 444.09m; shareholders' equity fell 86.6% to USD 48.81m, from USD 363.82m.
Year ended 31 Dec 2025. Source: 10-K filed 17 Feb 2026, read it on SEC EDGAR.
USD 1.02bn to USD 1.40bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 1.02bn | 1.40bn | Up 37.6% |
| Net income | 444.09m | 316.89m | Down 28.6% |
| Total assets | 2.06bn | 2.53bn | Up 22.4% |
| Total liabilities | 1.70bn | 2.48bn | Up 45.7% |
| Long-term debt | 1.51bn | 2.14bn | Up 42.3% |
| Cash and cash equivalents | 115.85m | 133.82m | Up 15.5% |
| Shareholders' equity | 363.82m | 48.81m | Down 86.6% |
Questions people ask
Did Halozyme Therapeutics, Inc.'s revenue grow last year?
Revenue grew 37.6%, from USD 1.02bn to USD 1.40bn in the year ended 31 Dec 2025.
Is Halozyme Therapeutics, Inc. profitable?
Yes. Net income was USD 316.89m in the year ended 31 Dec 2025. The year before: USD 444.09m.
How much cash and debt does Halozyme Therapeutics, Inc. have?
At its latest year end (31 Dec 2025), Halozyme Therapeutics, Inc. reported cash and cash equivalents of USD 133.82m and long-term debt of USD 2.14bn.
Where do these numbers come from?
From Halozyme Therapeutics, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Halozyme Therapeutics, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Biological Products, (No Diagnostic Substances) companies
- Amgen Inc.Net income up 88.5%
- Gilead Sciences, Inc.Net income up 1672.9%
- Moderna, Inc.Revenue down 39.9%
- Revolution Medicines, Inc.Total liabilities up 146.7%
- Biogen Inc.Net income down 20.8%
- Exelixis IncCash and cash equivalents up 122%
- Neurocrine Biosciences IncCash and cash equivalents up 206%
- Repligen CorpCash and cash equivalents down 25.3%